Aquestive Therapeutics Advances Its Portfolio with Key Regulatory and Licensing Milestones

FDA Acceptance of Anaphylm™ NDA Resubmission

On October 15 2026, the U.S. Food and Drug Administration (FDA) formally accepted the resubmission of the New Drug Application (NDA) for Anaphylm™ (dibutepinephrine), a sublingual film intended to treat Type I allergic reactions, including anaphylaxis. The agency designated a Prescription Drug User Fee Act (PDUFA) goal date of March 16, 2027, classifying the resubmission as a Class 2 response.

Anaphylm represents the first and only oral rescue medication for severe allergic reactions, potentially transforming patient and caregiver access to epinephrine. The Company’s submission, lodged on September 16 2026 following positive topline data from human‑factor and pharmacokinetic studies, addresses all items raised in the FDA’s January 30, 2026 Complete Response Letter.

Implications for the Company

  • A clear regulatory path forward, with a firm goal date, allows Aquestive to align clinical, commercial, and supply‑chain resources.
  • The potential approval of Anaphylm could establish the Company as a pioneer in oral epinephrine delivery, opening a market with limited competition.
  • The Company is concurrently preparing commercial launch assets, underscoring confidence that the product will reach patients rapidly if approved.

Parallel Progress in Canada

While the U.S. regulatory process proceeds, Aquestive remains on schedule to submit the Anaphylm NDA to Health Canada in Q4 2026. Successful Canadian approval would provide an early international launch, diversifying revenue streams and mitigating U.S. market concentration.

Strategic Licensing Deal with Eton Pharmaceuticals

In mid‑October, Eton Pharmaceuticals entered into an exclusive U.S. licensing agreement for LIBERVANT® (diazepam) buccal film, a seizure‑rescue formulation developed by Aquestive. This collaboration extends beyond the U.S. into the Canadian market, where Eton also secured exclusive rights to the same product.

  • Commercial Synergy: Eton’s established manufacturing and distribution capabilities accelerate market entry, while Aquestive benefits from shared development costs and broader geographic reach.
  • Portfolio Expansion: LIBERVANT complements Anaphylm’s focus on acute emergencies, reinforcing the Company’s position in the broader category of rapid‑action rescue therapies.

Market Context and Financial Outlook

  • Stock Performance: As of October 13 2026, the share price stands at $4.61, with a 52‑week range of $2.93–$7.55.
  • Valuation: The market capitalization is approximately $586 million, reflecting the market’s current valuation of the Company’s late‑stage pipeline.
  • Profitability Metrics: The price‑earnings ratio is negative (–7.21), indicative of the Company’s ongoing investment in research and regulatory progression rather than immediate profitability.

Forward‑Looking Perspective

With FDA acceptance and a clear PDUFA goal date, Aquestive is positioned to transition from regulatory milestones to commercialization. The strategic partnership with Eton not only accelerates product launch timelines but also diversifies revenue opportunities across seizure and allergic reaction indications.

The simultaneous pursuit of U.S. and Canadian approvals mitigates regulatory risk and allows the Company to capture early market share in multiple jurisdictions. Should Anaphylm and LIBERVANT secure approvals, the Company could transition from a research‑focused entity to a commercial biopharmaceutical player with a robust pipeline of first‑in‑class rapid‑action therapeutics.

Given these developments, investors should monitor the FDA’s March 2027 review outcome and the progress of the LIBERVANT launch strategy, both of which are likely to be pivotal catalysts for Aquestive’s valuation and long‑term growth trajectory.